Next-generation Sequencing Services Market worth $9.37 billion by 2031 - Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Oct. 23, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Next-generation Sequencing Services Market is projected to reach USD 9.37 billion by 2031 from USD 3.96 billion in 2026, at a CAGR of 18.8% during the forecast period.

Browse 593 market data Tables and 55 Figures spread through 436 Pages and in-depth TOC on "NGS Services Market- Global Forecast to 2031"

Next-generation Sequencing Services Market Size & Forecast:

• Market Size Available for Years: 2026–2031
• 2026 Market Size: USD 3.96 billion
• 2031 Projected Market Size: USD 9.37 billion
• CAGR (2026–2031): 18.8%

Next-generation Sequencing Services Market Trends & Insights:

• North America accounted for the largest share of 40.9% of the NGS services market in 2025.
• By type, sequencing services accounted for the largest share of 75.6% of the NGS services market in 2025.
• By workflow, sequencing accounted for the largest share, at 84.5%, of the NGS services market in 2025.
• By application, diagnostic applications accounted for the largest share, at 47.7%, of the NGS services market in 2025.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194102241

The NGS services market is expanding as pharmaceutical and biotechnology companies, hospitals and clinical laboratories, and academic research institutes increasingly outsource sequencing workflows to support drug discovery, clinical research, precision medicine, population genomics, and biomarker development. NGS services are widely used for whole-genome sequencing, exome and targeted sequencing, RNA sequencing, de novo sequencing, ChIP sequencing, and methyl sequencing. Growing demand for high-throughput genomic analysis is also increasing the use of presequencing services and downstream bioinformatics support. The rising adoption of long-read sequencing services and customized NGS workflows is further widening the market opportunity. In addition, increasing requirements for data analysis, visualization, interpretation, and storage are strengthening demand for integrated service offerings. These capabilities help customers access advanced sequencing technologies without substantial capital investment, improve workflow scalability, and support complex research and clinical applications.

By type, the sequencing services segment held the largest share of the NGS services market in 2025.

By type, the NGS services market is segmented into presequencing services, sequencing services, bioinformatics & data analysis services, and NGS platform services. In 2025, sequencing services accounted for the largest market share. This is primarily due to the broad use of whole-genome sequencing, exome and targeted resequencing, RNA sequencing, de novo sequencing, ChIP sequencing, and methyl sequencing across clinical research and life science applications. Pharmaceutical and biotechnology companies increasingly outsource sequencing to access advanced platforms without making large capital investments. Hospitals and clinical laboratories also use these services for cancer diagnostics, infectious disease testing, and reproductive health applications. The need for specialized expertise, high-throughput capabilities, and reliable quality control further supports demand. Growing population genomics programs and wider use of NGS in drug discovery are also strengthening sequencing services' position in the market.

By workflow, the sequencing segment held the largest share of the NGS services market in 2025.

By workflow, the NGS services market is segmented into pre-sequencing, sequencing, and data analysis. In 2025, sequencing accounted for the largest market share. This is mainly due to the extensive use of sequencing workflows across whole-genome sequencing, exome and targeted sequencing, RNA sequencing, de novo sequencing, ChIP sequencing, and methyl sequencing. Sequencing represents the core revenue-generating stage of NGS service delivery and requires access to advanced platforms, skilled personnel, and high-throughput laboratory infrastructure. Pharmaceutical and biotechnology companies increasingly outsource this stage to support biomarker discovery, drug development, and translational research. Hospitals and clinical laboratories also rely on sequencing workflows for cancer, infectious disease, and reproductive health applications. Growing population genomics programs and rising demand for customized NGS studies further support the sequencing workflow segment's leading position.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=194102241

By region, North America accounted for the largest share of the market in 2025.

In 2025, North America held the largest share of the NGS services market. This is supported by strong genomics research infrastructure, high adoption of outsourced sequencing workflows, substantial investment in precision medicine and drug development, and the presence of leading pharmaceutical and biotechnology companies, hospitals, clinical laboratories, and research institutes. The region also benefits from large-scale population genomics programs and increasing use of NGS in cancer diagnostics, infectious disease testing, and reproductive health applications. Growing demand for whole-genome sequencing, RNA sequencing, targeted sequencing, and advanced bioinformatics services continues to support market growth. Wider adoption of long-read sequencing and customized NGS services is further strengthening North America's position in the global market.

Key Players

Leading players in the Next-generation Sequencing Services companies include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Eurofins Scientific (Luxembourg), Azenta US Inc. (US), BGI Group (China), Revvity (US), Agilent Technologies, Inc. (US), PacBio (US), Oxford Nanopore Technologies plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), and LGC Limited (UK), among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=194102241

Next-generation Sequencing Services Market - Investment & funding +Merger & Acquisition

Investment and Funding Context

The NGS services market is witnessing increasing investment, driven by rising demand for genomic diagnostics, research sequencing, precision medicine, and integrated bioinformatics services. Funding activity is increasingly focused on expanding sequencing capacity, strengthening clinical genomics capabilities, broadening geographic reach, and supporting end-to-end genomic analysis. Service providers are also investing in advanced sequencing workflows and data interpretation to address growing research and clinical requirements. For instance, in July 2025, MedGenome raised USD 47.5 million in Series E funding, co-led by Maj Invest and Novo Holdings. The funding is intended to expand access to MedGenome's genomics and integrated diagnostics offerings across India and other emerging markets. The investment highlights the growing strategic value of scalable sequencing, genomic diagnostics, and research services within the NGS services market.

Revenue Shift Context

The NGS services market is gradually shifting revenue from standardized sequencing offerings to higher-value services such as long-read sequencing, single-cell and spatial sequencing, customized NGS workflows, and integrated bioinformatics & data analysis. The global NGS services market is projected to increase from USD 3.96 billion in 2026 to USD 9.37 billion by 2031, at a CAGR of 18.8%, with a growing share of revenue expected from advanced sequencing and data-intensive services. Conventional offerings such as whole-genome sequencing, whole-exome sequencing, RNA sequencing, and targeted sequencing remain an important revenue base. However, clinical-grade genomic testing, multi-omics analysis, population genomics programs, and advanced data interpretation services are gaining adoption across academic research, pharmaceutical and biotechnology, and clinical settings.

Mergers and Acquisitions

Mergers and acquisitions in the NGS services market are being driven by the need to broaden sequencing portfolios, strengthen bioinformatics and data interpretation capabilities, expand clinical genomics services, and increase access to advanced areas such as long-read sequencing, single-cell analysis, population genomics, and precision medicine workflows.

NGS SERVICES MARKET: MERGERS AND ACQUISITIONS, JANUARY 2023–AUGUST 2026

Company Revenue Share Details

The top five players collectively account for approximately 36–41% of the global NGS services market, indicating a competitive landscape. This reflects the presence of numerous specialized sequencing, genomics, clinical testing, and bioinformatics service providers alongside large global life sciences companies. Key market participants include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Eurofins Scientific (Luxembourg), Azenta US, Inc. (US), BGI Group (China), Revvity (US), Agilent Technologies, Inc. (US), PacBio (US), Oxford Nanopore Technologies plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), and LGC Limited (UK). These companies compete through broad sequencing capabilities, specialized NGS workflows, geographic reach, laboratory infrastructure, bioinformatics expertise, and support for research and clinical applications. Continued expansion into long-read sequencing, customized NGS services, clinical genomics, and integrated data analysis is further shaping competition in the market.

Browse Adjacent Market: Biotechnology Market Research Reports &Consulting

See More Latest Biotechnology Reports:

Next-generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Application, Competition - Global Forecast to 2031

Bioinformatics Market by Offerings (Software (Genomics, Multiomics, Proteomics), Services (Analysis, Sequencing)), Function (Variant & Structural Analysis), Use Case (Drug Discovery, Biomarker), End User (Pharma & Biotech, CROs) - Global Forecast to 2031

About MarketsandMarkets™  

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/next-generation-sequencing-services-companies.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/ngs-services.asp